dcas13b adar2dd plasmid Search Results


psp dcas13b adar2dd e488q delta 984 1090  (Addgene inc)
93
Addgene inc psp dcas13b adar2dd e488q delta 984 1090
50nt PspdCas13b sgRNA with Tiled A-C Mismatch Do Not Edit the Endogenous E198K site in patient-derived neural stem cells. (A) Amplicon sequencing results of the relative read number of wild-type (GAA) and E198K (AAA) reads in E198K NSCs transfected with sgRNA and <t>dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090</t> plasmid construct. (B) Amplicon sequencing results of E198K NSCs transfected with PPIB sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. Percent editing was determined as the number of edited transcript reads over not edited transcripts in the treated group and normalized to not-treated E198K NSCs. *significantly different from not treated E198K NSCs, t-test P < .05. (C-F) Amplicon sequencing results of percent editing of the E198K site in E198K NSCs following screen with sgRNA of increasing length and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05. (G—J) Amplicon sequencing results of percent editing of the E198K site in E198K NSCS following screen with sgRNA 190 and variable A-C mismatch position and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05.
Psp Dcas13b Adar2dd E488q Delta 984 1090, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dcas13b+adar2dd+plasmid/pmc11811633-90-12-14?v=Addgene+inc
Average 93 stars, based on 1 article reviews
psp dcas13b adar2dd e488q delta 984 1090 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
dcas13b haddr2  (Addgene inc)
93
Addgene inc dcas13b haddr2
50nt PspdCas13b sgRNA with Tiled A-C Mismatch Do Not Edit the Endogenous E198K site in patient-derived neural stem cells. (A) Amplicon sequencing results of the relative read number of wild-type (GAA) and E198K (AAA) reads in E198K NSCs transfected with sgRNA and <t>dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090</t> plasmid construct. (B) Amplicon sequencing results of E198K NSCs transfected with PPIB sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. Percent editing was determined as the number of edited transcript reads over not edited transcripts in the treated group and normalized to not-treated E198K NSCs. *significantly different from not treated E198K NSCs, t-test P < .05. (C-F) Amplicon sequencing results of percent editing of the E198K site in E198K NSCs following screen with sgRNA of increasing length and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05. (G—J) Amplicon sequencing results of percent editing of the E198K site in E198K NSCS following screen with sgRNA 190 and variable A-C mismatch position and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05.
Dcas13b Haddr2, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dcas13b+adar2dd+plasmid/bio_rxiv__2022__01__25__477620-31-9-10?v=Addgene+inc
Average 93 stars, based on 1 article reviews
dcas13b haddr2 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
psp dcas13b adar2dd  (Addgene inc)
93
Addgene inc psp dcas13b adar2dd
Top DEGs are not rescued by <t>PspdCas13b-ADAR2DD</t> constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp <t>dCas13b-ADAR2DD(E488Q),</t> Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp <t>dCas13b-ADAR2DD(E488Q/T375G),</t> or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.
Psp Dcas13b Adar2dd, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dcas13b+adar2dd+plasmid/pmc11811633-90-7-9?v=Addgene+inc
Average 93 stars, based on 1 article reviews
psp dcas13b adar2dd - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
addgene plasmids  (Addgene inc)
92
Addgene inc addgene plasmids
Top DEGs are not rescued by <t>PspdCas13b-ADAR2DD</t> constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp <t>dCas13b-ADAR2DD(E488Q),</t> Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp <t>dCas13b-ADAR2DD(E488Q/T375G),</t> or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.
Addgene Plasmids, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dcas13b+adar2dd+plasmid/pm36443367-350-23-23?v=Addgene+inc
Average 92 stars, based on 1 article reviews
addgene plasmids - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier

Image Search Results


50nt PspdCas13b sgRNA with Tiled A-C Mismatch Do Not Edit the Endogenous E198K site in patient-derived neural stem cells. (A) Amplicon sequencing results of the relative read number of wild-type (GAA) and E198K (AAA) reads in E198K NSCs transfected with sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. (B) Amplicon sequencing results of E198K NSCs transfected with PPIB sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. Percent editing was determined as the number of edited transcript reads over not edited transcripts in the treated group and normalized to not-treated E198K NSCs. *significantly different from not treated E198K NSCs, t-test P < .05. (C-F) Amplicon sequencing results of percent editing of the E198K site in E198K NSCs following screen with sgRNA of increasing length and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05. (G—J) Amplicon sequencing results of percent editing of the E198K site in E198K NSCS following screen with sgRNA 190 and variable A-C mismatch position and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05.

Journal: Stem Cells

Article Title: A de novo missense mutation in PPP2R5D alters dopamine pathways and morphology of iPSC-derived midbrain neurons

doi: 10.1093/stmcls/sxae068

Figure Lengend Snippet: 50nt PspdCas13b sgRNA with Tiled A-C Mismatch Do Not Edit the Endogenous E198K site in patient-derived neural stem cells. (A) Amplicon sequencing results of the relative read number of wild-type (GAA) and E198K (AAA) reads in E198K NSCs transfected with sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. (B) Amplicon sequencing results of E198K NSCs transfected with PPIB sgRNA and dPspCas13b--ADAR2DD(E488Q/T375G)-delta-984-1090 plasmid construct. Percent editing was determined as the number of edited transcript reads over not edited transcripts in the treated group and normalized to not-treated E198K NSCs. *significantly different from not treated E198K NSCs, t-test P < .05. (C-F) Amplicon sequencing results of percent editing of the E198K site in E198K NSCs following screen with sgRNA of increasing length and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05. (G—J) Amplicon sequencing results of percent editing of the E198K site in E198K NSCS following screen with sgRNA 190 and variable A-C mismatch position and PspdCas13b-ADAR2DD constructs. Percent editing was determined as the number of edited transcript reads over not edited transcripts in treated group and normalized to not-treated E198K. * ** and **** significantly different from respective construct with no gRNA control, one-way ANOVA P < .05.

Article Snippet: Four available Psp dCas13b-ADAR2DD constructs were screened: Psp dCas13b-ADAR2DD(E488Q) (Addgene plasmid #103849), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090 (Addgene plasmid #103 869), Psp dCas13b-ADAR2DD(E488Q/T375G) (Addgene plasmid #103 870), and Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090 (Addgene plasmid #103 871).

Techniques: Derivative Assay, Amplification, Sequencing, Transfection, Plasmid Preparation, Construct, Control

Top DEGs are not rescued by PspdCas13b-ADAR2DD constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp dCas13b-ADAR2DD(E488Q), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp dCas13b-ADAR2DD(E488Q/T375G), or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.

Journal: Stem Cells

Article Title: A de novo missense mutation in PPP2R5D alters dopamine pathways and morphology of iPSC-derived midbrain neurons

doi: 10.1093/stmcls/sxae068

Figure Lengend Snippet: Top DEGs are not rescued by PspdCas13b-ADAR2DD constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp dCas13b-ADAR2DD(E488Q), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp dCas13b-ADAR2DD(E488Q/T375G), or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.

Article Snippet: Four available Psp dCas13b-ADAR2DD constructs were screened: Psp dCas13b-ADAR2DD(E488Q) (Addgene plasmid #103849), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090 (Addgene plasmid #103 869), Psp dCas13b-ADAR2DD(E488Q/T375G) (Addgene plasmid #103 870), and Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090 (Addgene plasmid #103 871).

Techniques: Construct, Expressing, Quantitative RT-PCR

Top DEGs are not rescued by PspdCas13b-ADAR2DD constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp dCas13b-ADAR2DD(E488Q), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp dCas13b-ADAR2DD(E488Q/T375G), or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.

Journal: Stem Cells

Article Title: A de novo missense mutation in PPP2R5D alters dopamine pathways and morphology of iPSC-derived midbrain neurons

doi: 10.1093/stmcls/sxae068

Figure Lengend Snippet: Top DEGs are not rescued by PspdCas13b-ADAR2DD constructs and sgRNA 190. Relative expression of the 3 top DEGs between the isogenic and E198K NSC cell states in isogenic, not-treated E198K NSCs, E198K NSCs treated with Psp dCas13b-ADAR2DD(E488Q), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090, Psp dCas13b-ADAR2DD(E488Q/T375G), or Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090. (A) RWDD28 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (B) ZNF717 relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05. (C) CTSF relative expression determined by RT-qPCR. * Significantly different from total isogenic, one-way ANOVA P < .05.

Article Snippet: Four available Psp dCas13b-ADAR2DD constructs were screened: Psp dCas13b-ADAR2DD(E488Q) (Addgene plasmid #103849), Psp dCas13b-ADAR2DD(E488Q)-delta-984-1090 (Addgene plasmid #103 869), Psp dCas13b-ADAR2DD(E488Q/T375G) (Addgene plasmid #103 870), and Psp dCas13b-ADAR2DD(E488Q/T375G)-delta-984-1090 (Addgene plasmid #103 871).

Techniques: Construct, Expressing, Quantitative RT-PCR